Medpace Corporate

Executive Summary: Ophthalmic gene therapy clinical trials aim to correct or replace genes in the eye to slow, halt, or reverse inherited retinal diseases. Gene therapy has rapidly moved from concept to clinic in ophthalmology. The approval of voretigene neparvovec (Luxturna) for RPE65‑mediated retinal dystrophy demonstrated that targeted genetic...

As innovation accelerates across diabetes and endocrinology – particularly in areas like type 1 and type 2 diabetes, cell and gene therapies, and digital health integration – Sponsors must navigate incr...

Oncology and precision medicine trials continue to evolve, and histology & anatomic pathology has become increasingly important in supporting biomarker-driven research, tissue-based analyses, and translational science. Sponsors require laboratory partners that can both deliver reliable histology services and also integrate seamlessly with molecular and other specialty l...

In this brief Q&A, meet our two new in-house neurologists, and explore the background and perspective they both bring to advancing neuroscience research at Medpace. 

These highly qualified neurologists offer Sponsors deep expertise across a broad spectrum of diseases within neurodegenerative and neuromuscular indication...

Featuring: Dr. Sonia Quintas, MD, MSc, Theresa Veira, MSN, MBA, and Pora Kuperman, MPH, PhD

Migraine is a leading cause of disability in children and adolescents, with prevalence estimates of roughly 3% in younger children. Yet the clinical picture often diverges from adults, which strengthens the need for a specialized approach.<...